|
Apr 30
|
Clearmind Applies to Cease Being a Reporting Issuer in Canada
|
|
Feb 11
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jan 16
|
Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
|
|
Jan 16
|
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
|
|
Jan 11
|
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
|
|
Jan 10
|
Clearmind Medicine Completed Type A Meeting with the FDA
|
|
Dec 5
|
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
|
|
Dec 1
|
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
|
|
Nov 28
|
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
|
|
Nov 27
|
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
|
|
Nov 9
|
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
|
|
Sep 28
|
Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th
|
|
Aug 1
|
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
|
|
Aug 1
|
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
|
|
Jul 17
|
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
|